Comparison of cardiovascular effects of tiletamine-zolazepam, pentobarbital, and ketamine-xylazine in male rats.
We allocated 35 male Sprague-Dawley rats into 7 groups and anesthetized each by using one of the following regimens: ketamine 50 mg+xylaxine 5 mg; ketamine 75 mg+xylazine 5 mg; pentobarbital 45 mg; and Telazol 30, 40, 50, and 60 mg/kg; supplemental doses were used as required. Respiratory rate, heart rate, mean arterial pressure, cardiac index, and stroke index were measured every 30 min for 4 h. The Telazol groups showed a dose-dependent increase in duration of anesthesia. Duration of anesthesia was significantly shorter for the ketamine and pentobarbital groups than for any of the Telazol doses. Heart rate showed a dose-dependent decrease among the Telazol groups, but overall heart rate in these groups was higher than in the ketamine and pentobarbital groups. Mean arterial pressure in the Telazol 40 and 50 groups was significantly higher than the pentobarbital and higher ketamine groups yet lower than that of the Telazol 60 group. Overall animals anesthetized with Telazol showed the highest cardiac index, ketamine intermediate, and pentobarbital the lowest; cardiac index was higher in the Telazol 50 group than in either the Telazol 30 or pentobarbital groups. The pentobarbital group exhibited the lowest stroke index, whereas ketamine-treated animals had an intermediate stroke index. These differing effects of anesthetics on cardiovascular parameters must be considered when choosing an anesthesia regimen or comparing data from different studies. In our model, the Telazol 40 and 50 groups appeared to exhibit the fewest adverse cardiovascular effects.
Saha
Dhanonjoy C
DC
Department of Medicine, Saint Vincent's Catholic Medical Center of New York, New York Medical College, Valhalla, NY, USA. dsaha@UCHC.edu
Saha
Animita C
AC
Malik
Gautam
G
Astiz
Mark E
ME
Rackow
Eric C
EC
D000777:Anesthetics / Q000008:administration & dosage / Q000633:toxicity*; D019162:Anesthetics, Combined / Q000008:administration & dosage / Q000633:toxicity; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D004338:Drug Combinations; D006339:Heart Rate / Q000187:drug effects; D007649:Ketamine / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D010424:Pentobarbital / Q000008:administration & dosage / Q000633:toxicity*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012119:Respiration / Q000187:drug effects; D013992:Tiletamine / Q000008:administration & dosage / Q000633:toxicity*; D014991:Xylazine / Q000008:administration & dosage / Q000633:toxicity; D015041:Zolazepam / Q000008:administration & dosage / Q000633:toxicity*
D000777:Anesthetics; D019162:Anesthetics, Combined; D004338:Drug Combinations; C006131:tiletamine, zolazepam drug combination; D014991:Xylazine; D013992:Tiletamine; D007649:Ketamine; D015041:Zolazepam; D010424:Pentobarbital